Optiver Holding B.V. purchased a new stake in DBV Technologies S.A. (NASDAQ:DBVT – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 39,537 shares of the company’s stock, valued at approximately $75,000.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Commonwealth Equity Services LLC bought a new stake in shares of DBV Technologies in the third quarter valued at approximately $26,000. Two Sigma Investments LP grew its stake in DBV Technologies by 80.9% during the third quarter. Two Sigma Investments LP now owns 35,920 shares of the company’s stock valued at $64,000 after acquiring an additional 16,066 shares in the last quarter. Envestnet Asset Management Inc. grew its stake in DBV Technologies by 43.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 54,497 shares of the company’s stock valued at $83,000 after acquiring an additional 16,469 shares in the last quarter. BNP Paribas Arbitrage SNC increased its holdings in DBV Technologies by 74.2% during the 2nd quarter. BNP Paribas Arbitrage SNC now owns 39,034 shares of the company’s stock worth $74,000 after acquiring an additional 16,626 shares during the period. Finally, BNP Paribas Arbitrage SA purchased a new stake in DBV Technologies in the 2nd quarter worth approximately $49,000. Institutional investors own 23.90% of the company’s stock.
DBV Technologies Stock Performance
DBV Technologies stock opened at $0.85 on Tuesday. The firm’s fifty day moving average price is $1.17 and its 200-day moving average price is $1.55. The stock has a market cap of $163.86 million, a P/E ratio of -1.52 and a beta of 1.19. DBV Technologies S.A. has a fifty-two week low of $0.82 and a fifty-two week high of $2.37.
Analyst Ratings Changes
A number of research firms have recently commented on DBVT. StockNews.com upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Friday, November 10th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of DBV Technologies in a research note on Monday, November 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $4.00 price target on shares of DBV Technologies in a report on Tuesday, August 1st. Finally, The Goldman Sachs Group cut their price objective on DBV Technologies from $1.30 to $1.00 and set a “sell” rating for the company in a report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $5.00.
DBV Technologies Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and eosinophilic esophagitis.
- Five stocks we like better than DBV Technologies
- Are Penny Stocks a Good Fit for Your Portfolio?
- The only two airline stocks worth buying: One is a Goldman pick
- How to Invest in Canada for Beginners
- Ride the momentum: Apparel stocks soaring at 52-week highs
- What Does a Stock Split Mean?
- Safeguard your portfolio with these three bargain stocks
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.